PTC Therapeutics, Inc. (PTCT) is a publicly traded Healthcare sector company. As of October 13, 2026, PTCT trades at $59.94 with a market cap of $5.25B and a P/E ratio of -98.42. PTCT moved -4.85% today. Year to date, PTCT is -21.92%; over the trailing twelve months it is -9.29%. Its 52-week range spans $35.95 to $90.87. Analyst consensus is buy with an average price target of $99.56. Rallies surfaces PTCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
PTC Therapeutics executive Mark Elliott Boulding disposes of $12,337 of common shares: Executive Vice President and CLO Mark Elliott Boulding exercised options for 192 shares at $39.42 on Oct. 9, 2026, then sold them at a weighted average price of $64.26. He held 105,272 shares directly after the transactions.
| Metric | Value |
|---|---|
| Price | $59.94 |
| Market Cap | $5.25B |
| P/E Ratio | -98.42 |
| EPS | $-0.65 |
| Dividend Yield | 0.00% |
| 52-Week High | $90.87 |
| 52-Week Low | $35.95 |
| Volume | 775.88K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.01B |
| Net Income | $-38.38M |
| Gross Margin | 0.00% |
10 analysts cover PTCT: 0 strong buy, 8 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $99.56.